Program
GV-971
Also written as “Sodium oligo-mannurarate 900mg”, “Sodium Oligomannate Capsules” and “Sodium Oligomannate Capsules (GV-971)”.
Its studies are mostly in Alzheimer Disease · Cognitive Dysfunction, led by 2 companies.
Drug pageGV-971: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Green Valley (Shanghai) Pharmaceuticalsits history only | 43 open or running | phase 4since May 16, 2021 | Aug 11, 2020 | Jun 2029phase 4 · NCT05908695 |
| Shanghai Greenvalley Pharmaceutical | 40 open or running | phase 3since Nov 13, 2014 | Sep 30, 2011 | none ahead |
- Named in fosun pharma’s own pipeline as
GV-971
, phase 3, as of Sep 21, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Shanghai Greenvalley Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 30, 2011First study: phase 2 study in Alzheimer DiseaseFirst studyNCT01453569 · 255 enrolled · China
- Nov 13, 2014Phase 3 study in Cognitive DysfunctionNCT02293915 · 818 enrolled · China
- Dec 6, 2016Phase 1 study in BioavailabilityNCT02986529 · 15 enrolled · China
- Oct 15, 2018Phase 1 study in PharmacokineticsNCT03715114 · 45 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 Shanghai Greenvalley Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03715114Pharmacokinetics · China | 1 | UNKNOWN | Nov 30, 2018 | 45 |
| NCT02986529Bioavailability · China | 1 | Completed | Feb 24, 2017 | 15 |
| NCT02293915Cognitive Dysfunction · China | 3 | Completed | Jun 29, 2018 | 818 |
| NCT01453569Alzheimer Disease · China | 2 | Completed | Aug 2013 | 255 |
How it is read
Names in the registry
- “GV-971”, 4 entries
- “Sodium oligo-mannurarate 900mg”, 2 entries
- “Sodium Oligomannate Capsules”, 1 entry
- “Sodium Oligomannate Capsules (GV-971)”, 1 entry
- “Sodium oligo-mannurarate 600mg”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 5 studies
- Cognitive Dysfunction, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.